Profile data is unavailable for this security.
About the company
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
- Revenue in USD (TTM)4.59bn
- Net income in USD36.00m
- Incorporated2018
- Employees9.00k
- LocationElanco Animal Health Inc450 ELANCO CIRCLEINDIANAPOLIS 46221United StatesUSA
- Websitehttps://www.elanco.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc | 174.33m | -197.71m | 6.54bn | 283.00 | -- | 43.94 | -- | 37.54 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| Krystal Biotech Inc | 373.16m | 198.91m | 8.02bn | 275.00 | 41.49 | 7.04 | 39.21 | 21.48 | 6.66 | 6.66 | 12.50 | 39.26 | 0.3358 | 0.7616 | 3.29 | 1,356,960.00 | 17.90 | -4.81 | 19.49 | -5.07 | 94.26 | -- | 53.30 | -41.51 | 9.73 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Axsome Therapeutics Inc | 561.26m | -229.53m | 9.14bn | 683.00 | -- | 123.65 | -- | 16.28 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Halozyme Therapeutics, Inc. | 1.24bn | 595.49m | 9.34bn | 350.00 | 16.70 | 18.53 | 13.79 | 7.52 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 10.11bn | 2.80k | -- | 2.55 | 31.80 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.28bn | 391.00 | -- | 5.67 | -- | 540.34 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 11.50bn | 3.04k | 22.44 | 1.90 | 19.07 | 3.72 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 12.46bn | 2.00k | 26.62 | 3.82 | 24.49 | 4.35 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.49bn | 9.00k | 350.88 | 1.85 | 17.69 | 2.72 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| BridgeBio Pharma Inc | 353.78m | -797.12m | 14.50bn | 725.00 | -- | -- | -- | 40.99 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 16.50bn | 5.80k | -- | 1.91 | -- | 8.49 | -7.26 | -7.26 | 5.00 | 22.14 | 0.1468 | 5.34 | 7.17 | -- | -21.31 | 10.19 | -25.32 | 13.43 | 62.91 | 75.16 | -145.16 | 19.02 | 3.22 | -- | 0.0659 | -- | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| Viatris Inc | 14.12bn | -3.69bn | 18.16bn | 32.00k | -- | 1.20 | -- | 1.29 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
Data as of Feb 17 2026. Currency figures normalised to Elanco Animal Health Inc's reporting currency: US Dollar USD
69.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Dec 2025 | 79.08m | 15.92% |
| PRIMECAP Management Co.as of 31 Dec 2025 | 46.21m | 9.30% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 44.27m | 8.91% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 40.81m | 8.21% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 39.65m | 7.98% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 31.51m | 6.34% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 24.17m | 4.86% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 15.05m | 3.03% |
| FIAM LLCas of 30 Sep 2025 | 14.62m | 2.94% |
| Strategic Advisers LLCas of 30 Sep 2025 | 11.09m | 2.23% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
